Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R03) | Apply Online

Opportunity Summary:

The NIH Funding Opportunity Announcement PA-06-267, titled "Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R03)," is designed to spark smaller, targeted research projects that dig into why temporomandibular joint and muscle disorders (TMJMDs) so often overlap with a wider cluster of chronic conditions. TMJMDs are described as a complex set of disorders affecting one or more tissues of the temporomandibular joint and the muscles of the face. The core clinical picture typically includes persistent pain in the facial muscles along with limited, painful jaw movement. What makes this FOA distinctive is its emphasis on the frequent coexistence of TMJMD symptoms with other long-lasting illnesses and symptom syndromes, suggesting there may be shared biological or behavioral pathways driving multiple conditions at once.

A central goal of the announcement is to encourage investigators to use modern, multidisciplinary and interdisciplinary methods to identify etiological and pathophysiological mechanisms that could explain these overlaps. The FOA explicitly calls for state-of-the-art approaches that can integrate molecular, physiological, and behavioral science to explain shared or interacting symptom patterns. Rather than treating TMJMDs as isolated jaw and facial pain problems, the announcement frames them as potentially connected to broader systemic or neurologic mechanisms that could also contribute to comorbid disorders. The list of comorbidities highlighted in the FOA is wide-ranging and includes fibromyalgia, atypical face pain, trigeminal neuralgia, chronic fatigue syndrome, multiple chemical sensitivity, irritable bowel syndrome, complex regional pain syndrome, migraine headache, and a variety of communication and sensory-related disorders (speech, hearing, swallowing, balance, smell, and taste). It also mentions certain cardiovascular diseases, reinforcing that the NIH is interested in cross-cutting mechanisms that might bridge seemingly different diagnostic categories.

In terms of the kind of science NIH is looking for, applications can center either on TMJMDs themselves or on one of the comorbid conditions, as long as the project is clearly aimed at uncovering the biological mechanisms linking TMJMDs with the comorbidity. The FOA recognizes that the overall scientific challenge is bigger than what any single small grant can solve, so it encourages applicants to narrow their focus to a specific disease comorbid with TMJMD and a particular pathway or mechanistic hypothesis. In practical terms, that means a competitive application would not just document that two conditions co-occur; it would be built around a plausible mechanistic link and a plan to test it, whether the mechanism is molecular signaling, neural processing, immune or inflammatory pathways, endocrine or stress-response systems, pain modulation networks, or behavioral and psychosocial contributors that interact with physiology.

This opportunity uses the NIH R03 Small Research Grant mechanism, which is tailored for short, limited-resource projects. The FOA emphasizes that R03 awards are meant to support work such as pilot and feasibility studies, secondary analysis of existing datasets, small self-contained research projects, development of research methods, or early development of new research technologies. The R03 is also explicitly non-renewable, underscoring that it is intended as a focused, time-limited effort that can generate preliminary data, refine methods, or open a new line of investigation that could later scale into larger projects.

Funding limits are set at up to $50,000 per year in direct costs, with a project period of up to two years, for a maximum of $100,000 in direct costs across the entire project. Like many NIH announcements, the FOA notes that actual awards depend on the availability of funds and the receipt of enough high-quality applications. The announcement also points out that this R03 program runs in parallel with other FOAs of the same scientific scope that use different grant mechanisms: PA-06-188 for the R01 (larger, more comprehensive research projects) and PA-06-268 for the R21 (exploratory/developmental projects). That parallel structure signals that NIH is trying to build a pipeline of research at multiple scales, from smaller early-stage studies to more extensive programs of research, all centered on mechanistic links between TMJMDs and comorbid conditions.

Eligibility is broad. A wide range of applicant organizations can apply, including for-profit and non-profit entities; public or private institutions like universities, colleges, hospitals, and laboratories; units of state and local government; eligible federal agencies; domestic and foreign institutions; and faith-based or community-based organizations. Tribal governments and tribal organizations are also included among eligible applicants. On the investigator side, the FOA invites any individuals with the expertise and resources to carry out the proposed work to apply through their institutions, and it reiterates NIH-wide encouragement for participation by individuals from underrepresented racial and ethnic groups and individuals with disabilities. Applicants are also allowed to submit more than one application, as long as each submission is scientifically distinct.

Administratively, the FOA is a discretionary grant opportunity in the health category, associated with CFDA numbers 93.121 (Oral Diseases and Disorders Research) and 93.853 (Extramural Research Programs in the Neurosciences and Neurological Disorders). There is no cost sharing or matching requirement. The announcement was originally posted March 24, 2006, and it used multiple receipt dates, with the archived closing information showing a last listed receipt date of May 7, 2009 (and an archive date of June 7, 2009). The sponsoring agency is the National Institutes of Health, and the full announcement was hosted on the NIH grants website.

Browse more opportunities from the same agency: National Institutes of Health

Browse more opportunities from the same category: Health

Next opportunity: Temporomandibular Joint and Muscle Disorders Pathophysiological Mechanisms Linking Comorbid Conditions (R21)

Previous opportunity: Grants for Alzheimers Disease Drug Discovery (R21)

USGrants.org Applicant Portal:

Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.

Apply for PA 06 267

 

[Watch] how do funding administrators access proposals?

Applicants also applied for:

Applicants who have applied for this opportunity (PA 06 267) also looked into and applied for these:

 

Grant application guides and resources

It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!

Apply for Grants

 

 

Premium leads for funding administrators, grant writers, and loan issuers

Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.

If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.

Subscribe to Leads

 

Request more information:

Would you like to learn more about this funding opportunity, similar opportunities to "PA 06 267", eligibility, application service, and/or application tips? Submit an inquiry below:

Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.